Sie sind hier:



T. Koch, C. Dahlke, A. Fathi, A. Kupke, V. Krähling, N. M. A. Okba, S. Halwe, C. Rohde, M. Eickmann, A. Volz, T. Hesterkamp, A. Jambrecina, S. Borregaard, M. L. Ly, M. E. Zinser, E. Bartels, J. S. H. Poetsch, R. Neumann, R. Fux, S. Schmiedel, A. W. Lohse, B. L. Haagmans, G. Sutter, S. Becker, M. M. Addo. Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial. Lancet. Infect. Dis. 2020: 20(7):827-838. doi: 10.1016/S1473-3099(20)30248-6.

D. Forster, J. H. Schwarz, K. Brosinski, U. Kalinke, G. Sutter, A. Volz. Obstetric Ultrasonography to Detect Fetal Abnormalities in a Mouse Model for Zika Virus Infection. Viruses. 2020: 12(1):72. doi: 10.3390/v12010072.




G. Kalodimou, S. Veit, S. Jany, U. Kalinke, C. C. Broder, G. Sutter, A. Volz. A Soluble Version of Nipah Virus Glycoprotein G Delivered by Vaccinia Virus MVA Activates Specific CD8 and CD4 T Cells in Mice. Viruses. 2019: 12(1):26. doi: 10.3390/v12010026.




S. Veit, S. Jany, R. Fux, G. Sutter, A. Volz. CD8+ T Cells Responding to the Middle East Respiratory Syndrome Coronavirus Nucleocapsid Protein Delivered by Vaccinia Virus MVA in Mice. Viruses. 2018: 10(12):718. doi: 10.3390/v10120718.

R. Schmidt, L. C. Beltzig, B. Sawatsky, O. Dolnik, E. Dietzel, V. Krähling, A. Volz, G. Sutter, S. Becker, V. von Messling. Generation of therapeutic antisera for emerging viral infections. NPJ Vaccines. 2018: 3:42. doi: 10.1038/s41541-018-0082-4. eCollection 2018.

K. A. Tappe, R. Budida, M. V. Stankov, T. Frenz, H. R. Shah, A. Volz, G. Sutter, U. Kalinke, G. M. N. Behrens. Immunogenic cell death of dendritic cells following modified vaccinia virus Ankara infection enhances CD8 + T cell proliferation. Eur. J. Immunol. 2018: 48(12):2042-2054. doi: 10.1002/eji.201847632. Epub 2018 Oct 10.

M. C. Langenmayer, A.-T. Lülf-Averhoff, S. Adam-Neumair, G. Sutter, A. Volz. Tracking Modified Vaccinia Virus Ankara in the Chicken Embryo: In Vivo Tropism and Pathogenesis of Egg Infections. Viruses. 2018: 10(9):452. doi: 10.3390/v10090452.

M. C. Langenmayer, A.-T. Lülf-Averhoff, S. Adam-Neumair, R. Fux, G. Sutter, A. Volz. Distribution and absence of generalized lesions in mice following single dose intramuscular inoculation of the vaccine candidate MVA-MERS-S. Biologicals. 2018: 54:58-62. doi: 10.1016/j.biologicals.2018.05.004.

A. Volz, S. Jany, A. Freudenstein, M. Lantermann, H. Ludwig, G. Sutter. E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox. Viruses. 2018: 10(1):21. doi: 10.3390/v10010021.




A. F. Altenburg, C. E. van de Sandt, B. W. S. Li, R. J. MacLoughlin, R. A. M. Fouchier, G. van Amerongen, A. Volz, R. W. Hendriks, R. L. de Swart, G. Sutter, G. F. Rimmelzwaan, R. D. de Vries. Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo. Sci. Rep. 2017: 7(1):8580. doi: 10.1038/s41598-017-08719-y.

E. K. Link, C. Brandmüller, Y. Suezer, S. Ameres, A. Volz, A. Moosmann, G. Sutter, M. H. Lehmann. A synthetic human cytomegalovirus pp65-IE1 fusion antigen efficiently induces and expands virus specific T cells. Vaccine. 2017: 35(38):5131-5139. doi: 10.1016/j.vaccine.2017.08.019.

A. Volz, G. Sutter. Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development. Adv. Virus Res. 2017: 97:187-243. doi: 10.1016/bs.aivir.2016.07.001.




A.-T. Lülf, A. Freudenstein, L. Marr, G. Sutter, A. Volz. Non-plaque-forming virions of Modified Vaccinia virus Ankara express viral genes. Virology. 2016: 499:322-330. doi: 10.1016/j.virol.2016.09.006.

M. F. Ducatez, J. Becker, A. Freudenstein, M. Delverdier, M. Delpont, G. Sutter, J.-L. Guérin, A. Volz. Low pathogenic avian influenza (H9N2) in chicken: Evaluation of an ancestral H9-MVA vaccine. Vet. Microbiol. 2016: 189:59-67. doi: 10.1016/j.vetmic.2016.04.025.

A. Volz, S. Lim, M. Kaserer, A. Lülf, L. Marr, S. Jany, C. A. Deeg, G. P. Pijlman, P. Koraka, A. D. M. E. Osterhaus, B. E. Martina, G. Sutter. Immunogenicity and protective efficacy of recombinant Modified Vaccinia virus Ankara candidate vaccines delivering West Nile virus envelope antigens. Vaccine. 2016: 34(16):1915-26. doi: 10.1016/j.vaccine.2016.02.042.

L. Marr, A.-T. Lülf, A. Freudenstein, G. Sutter, A. Volz. Myristoylation increases the CD8+T-cell response to a GFP prototype antigen delivered by modified vaccinia virus Ankara. J. Gen. Virol. 2016: 97(4):934-940. doi: 10.1099/jgv.0.000425.

B. L. Haagmans, J. M. A. van den Brand, V. Stalin Raj, A. Volz, P. Wohlsein, S. L. Smits, D. Schipper, T. M. Bestebroer, N. Okba, R. Fux, A. Bensaid, D. Solanes Foz, T. Kuiken, W. Baumgärtner, J. Segalés, G. Sutter, A. D. M. E. Osterhaus. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science. 2016: 351(6268):77-81. doi: 10.1126/science.aad1283.




A. Volz, R. Fux, M. C. Langenmayer, G. Sutter. [Modified vaccinia virus ankara (MVA)--development as recombinant vaccine and prospects for use in veterinary medicine]. Berl. Munch. Tierarztl. Wochenschr. 2015: 128(11-12):464-72.

A. Volz, A. Kupke, F. Song, S. Jany, R. Fux, H. Shams-Eldin, J. Schmidt, C. Becker, M. Eickmann, S. Becker, G. Sutter. Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein. J. Virol. 2015: 89(16):8651-6. doi: 10.1128/JVI.00614-15.




P. van den Doel, A. Volz, J. M. Roose, V. D. Sewbalaksing, G. P. Pijlman, I. van Middelkoop, V. Duiverman, E. van de Wetering, G. Sutter, A. D. M. E. Osterhaus, B. E. E. Martina. Recombinant modified vaccinia virus Ankara expressing glycoprotein E2 of Chikungunya virus protects AG129 mice against lethal challenge. PLoS Negl. Trop. Dis. 2014: 8(9):e3101. doi: 10.1371/journal.pntd.0003101.

A. F. Altenburg, J. H. C. M. Kreijtz, R. D. de Vries, F. Song, R. Fux, G. F. Rimmelzwaan, G. Sutter, A. Volz. Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. Viruses. 2014: 6(7):2735-61. doi: 10.3390/v6072735.

A. Volz, M. Langenmayer, S. Jany, U. Kalinke, G. Sutter. Rapid expansion of CD8+ T cells in wild-type and type I interferon receptor-deficient mice correlates with protection after low-dose emergency immunization with modified vaccinia virus Ankara. J. Virol. 2014: 88(18):10946-57. doi: 10.1128/JVI.00945-14.





F. Song, R. Fux, L. B. Provacia, A. Volz, M. Eickmann, S. Becker, A. D. M. E. Osterhaus, B. L. Haagmans, G. Sutter. Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. J. Virol. 2013: 87(21):11950-4. doi: 10.1128/JVI.01672-13.




M. Kremer, A. Volz, J. H. C. M. Kreijtz, R. Fux, M. H. Lehmann, G. Sutter. Easy and efficient protocols for working with recombinant vaccinia virus MVA. Methods Mol. Biol. 2012: 890:59-92. doi: 10.1007/978-1-61779-876-4_4.

M. Kremer, Y. Suezer, A. Volz, T. Frenz, M. Majzoub, K.-M. Hanschmann, M. H. Lehmann, U. Kalinke, G. Sutter. Critical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpox. PLoS Pathog. 2012: 8(3):e1002557. doi: 10.1371/journal.ppat.1002557.




M. S. Gratz, Y. Suezer, M. Kremer, A. Volz, M. Majzoub, K.-M. Hanschmann, U. Kalinke, A. Schwantes, G. Sutter. N1L is an ectromelia virus virulence factor and essential for in vivo spread upon respiratory infection. J. Virol. 2011: 85(7):3557-69. doi: 10.1128/JVI.01191-10.


A. Volz, G. Sutter. Protective efficacy of Modified Vaccinia virus Ankara in preclinical studies. Vaccine. 2013: 31(39):4235-40. doi: 10.1016/j.vaccine.2013.03.016.


J. H. C. M. Kreijtz, M. Goeijenbier, F. M. Moesker, L. van den Dries, S. Goeijenbier, H. L. M. De Gruyter, M. H. Lehmann, G. de Mutsert, D. A. M. C. van de Vijver, A. Volz, R. A. M. Fouchier, E. C. M. van Gorp, G. F. Rimmelzwaan, G. Sutter, A. D. M. E. Osterhaus. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial. Lancet Infect. Dis. 2014: 14(12):1196-207. doi: 10.1016/S1473-3099(14)70963-6.


A. F. Altenburg, C. E. van de Sandt, S. E. van Trierum, H. L. M. De Gruyter, P. R. W. A. van Run, R. A. M. Fouchier, K. Roose, X. Saelens, A. Volz, G. Sutter, R. D. de Vries, G. F. Rimmelzwaan. Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice. J. Virol. 2016: 90(22):10209-10219. doi: 10.1128/JVI.01633-16.


M. Kubinski, J. Beicht, T. Gerlach, A. Volz, G. Sutter, G. F. Rimmelzwaan. Tick-Borne Encephalitis Virus: A Quest for Better Vaccines against a Virus on the Rise. Vaccines (Basel). 2020: 8(3):E451. doi: 10.3390/vaccines8030451.

Kontakt Geschäftszimmer
Bianca Beyersdorf
Tel.:+49 511 953-6130
Diese Seite